What Mabron Retard Treats: Main Uses and Benefits

Mabron retard is primarily used for the symptomatic relief and continuous management of moderate to severe pain. Its primary benefit supports the patient during difficult episodes by easing distress and assists with maintaining functional stability across several demanding clinical scenarios in situations where supportive symptom management is appropriate. The extended-release formulation is specifically used for persistent pain that generally requires around-the-clock treatment for an extended period.

The medicine is relevant for managing symptom clusters that may become intense or disruptive in conditions characterized by long-term pain, such as certain forms of chronic back pain or pain related to osteoarthritis. This formulation generally helps support consistent pain relief for extended periods, and may help patients cope more steadily with symptom fluctuations.

“This formulation generally helps support continuous relief, assisting with maintaining functional stability and supporting patients during episodes of heightened discomfort.”

It supports therapeutic domains focused on assisting with maintaining functional stability and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Symptomatic Support for Persistent Pain
Primary Indication Focus	Moderate to severe chronic pain
Primary Symptom Focus	Symptoms related to continuous physical discomfort
Benefit of Prolonged Release	Supports continuous relief for extended periods

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Profile: Mabron Retard (Tramadol)

This medication is only eligible for use by adults and adolescents older than 12 years who do not have specific contraindications. Eligibility is strictly defined by regulatory documentation to maximize safety and includes absolute exclusions and conditions that require restricted use.

Contraindicated Populations	Use Is Forbidden Due To Official Labeling
Patients with known hypersensitivity to tramadol	Patients currently taking MAO-inhibitors (or within 14 days of stopping)
Patients with uncontrolled epilepsy	Patients in a state of acute intoxication (alcohol, hypnotics, other CNS depressants)
Children under 12 years of age	Use for opioid withdrawal treatment

Eligibility is further restricted for specific groups. The medicine is not recommended for women who are breastfeeding. Use is conditional and requires careful medical evaluation and likely dose adjustment for patients with severe hepatic (liver) or renal (kidney) impairment and for those with pre-existing conditions such as head injuries or disturbances of the respiratory centre.

The interaction profile for Mabron retard (Tramadol Hydrochloride) is formally documented across several regulatory categories, defining strict co-administration constraints and required limitations.

Contraindicated Combinations and Constraints

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated. A mandatory separation period of 14 days is required after stopping MAOI therapy. Use is also contraindicated during acute intoxication involving alcohol, opioids, or other psychotropic medicinal products.

Pharmacodynamic Interactions

Combining Mabron retard with other Central Nervous System (CNS) depressants, such as sedatives or benzodiazepines, carries an increased risk of profound sedation and severe respiratory depression. Similarly, combining it with other serotonergic drugs (e.g., SSRIs, triptans) enhances the risk of Serotonin Syndrome. Interactions with seizure threshold-lowering drugs are documented to increase the overall risk of convulsions. Co-use with mixed agonist/antagonist opioids (e.g., buprenorphine) is not recommended as it may reduce the analgesic effect. Co-administration with Coumarin Derivatives (e.g., Warfarin) is associated with reports of increased bleeding risk.

Metabolic and Exposure Alterations

The clearance of Tramadol is influenced by hepatic enzymes. CYP2D6 Inhibitors may increase parent drug exposure, while CYP3A4 Inducers (like Carbamazepine) may decrease its effectiveness by accelerating metabolism. For the prolonged-release formulation, consumption of alcohol is restricted due to potentiated CNS depressant effects. Furthermore, the medicine is not recommended for patients with severe hepatic or renal impairment due to officially documented delayed elimination.

Dual Modulation of Nociceptive Pathways

Mabron retard modulates nociceptive signaling through two distinct, complementary mechanistic pathways. First, the active M1 metabolite is the primary ligand of the mu (μ) opioid receptor in the central nervous system, initiating a cascade that inhibits the release of nociceptive neurotransmitters at the synapse. Second, the parent drug blocks the reuptake of both serotonin and norepinephrine via their respective transporters in the spinal cord, thereby enhancing the descending inhibitory pathway. This combined action results in an alteration in nociceptive signal processing and central perception.

---

Dependence on Metabolism and Synergy

The magnitude of the physiological response is dependent on the drug's internal chemistry and delivery. As a racemic compound, its analgesic activity results from the complementary action of its two enantiomers and the M1 metabolite, exerting a complementary mechanistic action. Crucially, the activation of the μ-opioid receptor component is conditional on sufficient metabolism by the CYP2D6 enzyme, a genetic mechanism that influences the functional output of the μ-opioid receptor pathway by determining the amount of M1 formed. The prolonged-release formulation is integral to maintaining the sustained plasma concentration necessary to support this continuous metabolic conversion.

The administration of Mabron retard, a prolonged-release tablet, is strictly oral. This formulation is designed for either once daily or twice daily administration, establishing a scheduled pattern necessary for continuous analgesic action. Because the tablet utilizes a sustained-release mechanism, it must be swallowed whole and must not be cut, crushed, or chewed, as altering its physical structure compromises the intended release profile. While the tablets may be taken without regard to meals, it is emphasized to administer the dose at a consistent time each day.

The standard initial dose for adult patients who are opioid-naïve is typically 100 mg per day. The dosage can be adjusted in 100 mg increments based on response, but increases should not occur more frequently than every five days. The maximum daily dose for this prolonged-release form generally does not exceed 300 mg. The medicine is indicated for long-term use requiring around-the-clock relief, and the necessity of continued use is subject to periodic clinical assessment. When therapy is concluded, the dose must be gradually tapered over time to support cessation.

Specific rules govern use in certain populations: the prolonged-release tablet is not recommended for use in patients under 18 years of age. It is also generally not recommended for patients with severe kidney or liver impairment. For older adults (over 75 years), the dosage interval may need to be extended due to potential changes in the drug's elimination.

Research Evidence / Overview of Studies

This section provides an overview of the research studies and evidence base for the use of Mabron retard (tramadol hydrochloride extended-release). The data discussed below is intended for informational purposes only and does not constitute clinical advice or recommendations regarding treatment.

---

Study Goals and Initial Findings

Studies explored how the drug was observed to influence central nervous system signaling pathways. Research also examined whether this influence was associated with patient-reported pain and discomfort metrics.

Research investigated the effects of Mabron retard on patient-reported outcomes (PROs) and the time to onset of pain-related symptom changes. Early-stage (Phase 1/2) trials focused on defining appropriate dosage ranges and identifying common short-term effects.

---

Efficacy and Combination Therapy Studies

A major Phase 3 program was undertaken across multiple clinical sites. These pivotal trials enrolled adult participants to evaluate the primary endpoints related to specific chronic pain intensity scores.

• Monotherapy: Studies assessed the administration of Mabron retard alone over a fixed period. Findings reported metrics on pain intensity scores over the studied duration in the patient population.
• Combination Use: Follow-up research examined whether the use of Mabron retard with non-pharmacological therapies (e.g., physical therapy) influenced long-term functional status. These studies also evaluated co-administration effects with other common medications.

---

Safety Profile and Tolerability

The safety profile was assessed across all phases of clinical development. Discontinuation rates due to adverse events were recorded for each study arm. Research data remains limited for pediatric or elderly populations, as trial criteria typically focused on specific adult demographics.

Key Studies & References Tramadol pharmacokinetics and safety in specific populations: Elderly and renally impaired patients

Common questions about Mabron retard (FAQ)

Q: Is this medication safe to use during pregnancy?

According to official product information, this medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Regulatory documents indicate that the use of the medicine involves weighing the potential risks and benefits to the fetus.

Q: Does it make you sleepy or affect your ability to drive?

Regulatory documents indicate that this medication has been associated with central nervous system effects such as dizziness and somnolence (unusual drowsiness). Regulatory labeling suggests that patients should exercise caution regarding activities requiring mental alertness, such as driving or operating heavy machinery, until they know the effects of the medicine.

Q: Can children 2 years old use it?

The official labeling states that the safety and effectiveness of this medicine have not been established in pediatric patients. Official information indicates that use in patients 16 years of age and younger is typically not advised due to a lack of established safety and efficacy.

Q: Can I drink alcohol while on this medication?

Official information mentions that there have been reports of an increase in the intoxicating effects of alcohol when consumed by patients taking this medication. Regulatory documents mention that a reduction in alcohol consumption or stopping alcohol use may be appropriate for patients due to the potential for increased intoxicating effects.

How to Store and Dispose of Mabron retard

This information is based strictly on regulatory requirements found in official government documentation.

Official Storage Requirements

Mabron retard tablets do not require any special storage conditions, allowing for storage at ambient (room) temperature. The product has an official shelf-life of 3 years.

Storage Classification	Requirement
Temperature	No special conditions required
Packaging	Keep in original blister pack or container
Protection	Keep out of the sight and reach of children

Official Disposal Instructions

To dispose of unused or expired Mabron retard, users must follow the local requirements for pharmaceutical waste. The regulatory labeling instructs that the product should not be disposed of via household waste or wastewater in order to protect the environment. Disposal typically involves returning the medicine to a pharmacy or designated collection point.